AI Science Tracker
EN

Learned serum-marker combinations improve internal melanoma progression classification

University of the Basque Country; Biocruces Bizkaia Health Research Institute · 2 Jun 2020 · medicine

Discovery

Learned serum-marker combinations improve internal melanoma progression classification

Source check: Source checked. Not independent scientific confirmation.

Finding: In 323 early-stage melanoma patients, classifiers combined serum IL-4, GM-CSF and dermcidin with tumor thickness to distinguish subsequent metastatic progression. Nested internal validation supported added discrimination beyond thickness alone; this does not establish clinical benefit or external validity.

Technology: Regularized logistic regression; support vector machine; decision tree; naive Bayes; nearest neighbors

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Learned multivariable classifiers link measured circulating markers and tumor thickness to subsequent clinical outcomes.
Test and result
Classifiers were assessed with nested cross-validation in a clinical cohort with 74 metastatic outcomes. Scaling, oversampling, feature selection and tuning were assigned to the inner loop.
Limitation / still unknown
Internal validation only; unequal follow-up and incomplete sentinel-node information limit interpretation. This is postoperative risk classification, not diagnosis-time screening or an intervention benefit. Publisher first-online June 2 differs from the June 24 date in primary indexing metadata; the publisher date represents this journal version.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://febs.onlinelibrary.wiley.com/doi/10.1002/1878-0261.12732

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 21 Nov 2026. Review scope: Primary publisher front date and safe clinical/statistical Methods and Results. Operational assay sections are outside the represented evidence..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.